Opioid dependence is epidemic in the United States. While progress has been made in training providers, the gap in providing effective treatment of opioid use disorders continues to widen, moving beyond heroin addicted individuals to a much larger and diverse segment of the population. This increase is predominantly due to an alarming increase in addiction to prescription opioid analgesic medications.
Buprenorphine, the most recent addition to the pharmacotherapies available to treat opioid dependence, is novel among the opioid pharmacotherapies because of its partial agonist properties. It has been placed on Schedule III and is available by prescription from a physician’s office-based practice.
Recognizing the impact of this addiction, as well as learning how to treat opioid use disorders, are important steps in combating this ever growing medical problem. To obtain the waiver to prescribe, providers are required to take specialized training. PCSS-MAT uses the Half-and-Half format (first, 4.25 hours of face-to-face training with an instructor, followed by 3.75 hours of on-your-own-training that must be completed along with a post test). This training meets the requirements for physicians; however additional training is required for advanced practice providers.
The training focuses on specifics of treating patients with opioid use disorders in office-based settings and clinical vignettes to help trainees think through “real life” experiences in opioid use disorders treatment. Once the waiver training is completed in full, participants will receive a CME certificate of attendance from AAAP.
See brochure for complete information on credits.
By registering for this conference, you are granting permission for your contact information to be shared with the North Carolina Medical Society Foundation, which is a collaborating partner of this continuing education activity.
The program is recommended for prescribers in primary care, emergency medicine, pain management, psychiatric, HIV, and addiction medicine. (Not a prescriber? CLICK HERE)
- Define the federal Drug Abuse Treatment Act (DATA) of 2000 and the subsequent revisions that lists the criteria needed for Office-Based Opioid Treatment (OBOT)
- List the criteria for establishing the diagnosis of opioid dependence
- Distinguish between spontaneous withdrawal and precipitated withdrawal as well as the appropriate methods of buprenorphine induction
- Describe and contrast the functions of full mu agonists, partial agonists, and antagonists
- Explain the interplay between pain and addiction, and how buprenorphine can be used to help stabilize these patients
- Describe the basic approach used in at least three different types of non-pharmacological treatment of opioid dependence
- Describe three symptoms of opioid withdrawal or intoxication that mimic symptoms of a psychiatric disorder
- Describe at least three factors to consider in determining if the patient is an appropriate candidate for office-based treatment with buprenorphine
- Describe at least three areas that should be covered in the rules and expectations communicated to patients during the patient assessment process
- List at least three situations in which patient information, with patient identity, can be shared under current laws protecting the patient’s confidentiality 42 CFR and HIPAA
- Reduce and minimize buprenorphine misuse and diversion
- Describe the drug interactions of buprenorphine and pediatric exposures
Click here for a brochure
Click here for registration